Soligenix Inc

Soligenix Inc has a liquidity position characterized by a current ratio of 1.52 and a cash and equivalents balance of $9.41 million, which is significantly higher than its total liabilities of $6.40 million. The company's price-to-book ratio of 1.74 suggests that the market values the company at a premium to its book value, but this is not supported by profitability, as the company reported a net loss of $1.64 million and an operating loss of $1.74 million in the latest period.

The company's profitability metrics are weak, with a return on equity of -47.46% and a return on assets of -16.67%, both of which are significantly below the industry median for biotechnology firms. The company's operating cash flow of -$3.26 million and free cash flow of -$1.64 million indicate a lack of cash generation from operations, which is a concern for a company in the clinical-stage biopharmaceutical industry.

Soligenix's revenue is concentrated in a single business segment, as the company does not disclose multiple operating segments. The company's geographic exposure is primarily in the United States, as it is a U.S.-based biopharmaceutical company with no significant international operations disclosed in the financial data.

The company's growth trajectory is uncertain, as it has reported a revenue of $2.34 million in the latest period, but no growth metrics or future revenue projections are provided. The company's outlook for the current fiscal year is not specified, but the lack of profitability and cash flow generation suggests that the company may face challenges in sustaining operations without additional financing.

The risk assessment for Soligenix indicates a low risk of dilution and a low liquidity risk, as there are no immediate filing-based liquidity or dilution flags. However, the company's high debt-to-equity ratio of 0.79 and negative operating cash flow suggest that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders.

Recent events for Soligenix include the disclosure of a mean price target of $6.00 by analysts, with a median price target of $6.00 and a high price target of $10.00. The company has received one "buy" recommendation and no "strong buy" or "hold" recommendations, indicating a cautious outlook from analysts.

Analysts project 1527% upside to a $6.00 mean price target, signaling strong potential for significant share price appreciation.

The company maintains a low leverage band with zero debt-to-equity, reducing financial risk compared to highly leveraged peers.

Cash conversion metrics rank best-in-class within the biotechnology cohort, indicating superior efficiency in generating cash relative to peers.

Dilution and liquidity risks are assessed as low, suggesting manageable capital structure pressures and adequate market trading conditions.

Long-term debt decreased significantly from $9.9 million in 2022 to zero in 2026, strengthening the balance sheet over time.

The company generated negative free cash flow of $11.1 million in fiscal 2026, exacerbating cash burn and sustainability concerns.

Revenue $0.00; Operating income +4,7% YoY.

• ▍Revenue $0.00
• ▍Operating income +4,7% YoY
• ▍Net income +4,3% YoY
• ▍Free cash flow +4,3% YoY

Revenue $0.00; Operating income +6,4% YoY.

• ▍Revenue $0.00
• ▍Operating income +6,4% YoY
• ▍Net income +3,0% YoY
• ▍Free cash flow +3,0% YoY

Revenue $0.00; Operating income −38,4% YoY.

• ▍Revenue $0.00
• ▍Operating income −38,4% YoY
• ▍Net income −47,2% YoY
• ▍Free cash flow −47,3% YoY

Revenue $0.00, −100,0% YoY; Operating income −58,4% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −58,4% YoY
• ▍Net income −64,3% YoY
• ▍Free cash flow −64,4% YoY

Revenue $0.00; Operating income -$3.0M.

• ▍Revenue $0.00
• ▍Operating income -$3.0M

Revenue $0.00; Operating income -$3.7M.

• ▍Revenue $0.00
• ▍Operating income -$3.7M

Revenue $0.00; Operating income -$1.9M.

• ▍Revenue $0.00
• ▍Operating income -$1.9M

Revenue $2.3k; Operating income -$1.7M.

• ▍Revenue $2.3k
• ▍Operating income -$1.7M
• ▍Net margin -70277.8%

Revenue $0.00, −100,0% YoY; Operating income −25,5% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −25,5% YoY
• ▍Net income −34,0% YoY
• ▍Free cash flow −34,2% YoY

Revenue $119.4k, −85,8% YoY; Operating income −16,7% YoY.

• ▍Revenue $119.4k, −85,8% YoY
• ▍Operating income −16,7% YoY
• ▍Net income −34,6% YoY
• ▍Free cash flow −34,7% YoY
• ▍Net margin -6925.2%

Revenue $839.4k, −11,5% YoY; Operating income +43,2% YoY.

• ▍Revenue $839.4k, −11,5% YoY
• ▍Operating income +43,2% YoY
• ▍Net income +55,5% YoY
• ▍Free cash flow +55,5% YoY
• ▍Net margin -731.6%

Revenue $948.9k, +15,1% YoY; Operating income −12,3% YoY.

• ▍Revenue $948.9k, +15,1% YoY
• ▍Operating income −12,3% YoY
• ▍Net income −9,9% YoY
• ▍Free cash flow −10,0% YoY
• ▍Net margin -1454.1%